Hydroxychloroquine + Abemaciclib for Breast Cancer
(ABBY Trial)
Trial Summary
What is the purpose of this trial?
This is a Phase II randomized, controlled, open label breast cancer clinical trial. 66 patients will be enrolled. The drugs being studied are hydroxychloroquine (Plaquenil) and abemaciclib (also Verzenio). This research study is testing whether using these drugs to target the disseminated tumor cells in bone marrow can reduce their number or eliminate them. Both hydroxychloroquine and abemaciclib are pills that will be taken twice daily. Both are approved by the FDA
Will I have to stop taking my current medications?
The trial does not specify if you need to stop all current medications, but you cannot take tamoxifen due to interactions with hydroxychloroquine. You can continue adjuvant endocrine and bone modifying agents as per standard care guidelines.
What data supports the effectiveness of the drug combination of Hydroxychloroquine and Abemaciclib for breast cancer?
Research shows that Abemaciclib, when combined with endocrine therapy, is effective in reducing the risk of breast cancer recurrence in patients with hormone receptor-positive, HER2-negative breast cancer. It has also been shown to improve progression-free survival in advanced breast cancer when used as a first-line therapy.12345
What makes the drug combination of Hydroxychloroquine and Abemaciclib unique for breast cancer treatment?
This drug combination is unique because it combines Hydroxychloroquine, which is traditionally used for malaria and autoimmune diseases, with Abemaciclib, a CDK4/6 inhibitor that targets specific proteins involved in cell division. This combination may offer a novel approach for patients with hormone receptor-positive, HER2-negative breast cancer, especially after progression on other CDK4/6 inhibitors.13456
Research Team
Amy Clark
Principal Investigator
Abramson Cancer Center at Penn Medicine
Eligibility Criteria
This trial is for adults who've had invasive breast cancer diagnosed within the last 5 years and have finished primary treatments, except endocrine therapy. They must not show signs of cancer recurrence, be able to take oral meds, and meet specific health criteria like good organ function. Pregnant women or those not using birth control are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Abemaciclib and/or Hydroxychloroquine to target disseminated tumor cells in bone marrow
Safety Assessment
Incidence of treatment-emergent adverse events during cycle 1 of the safety cohort
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Abemaciclib
- Hydroxychloroquine
Abemaciclib is already approved in United States, European Union for the following indications:
- Hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer
- HR+, HER2- node-positive early breast cancer
- HR+, HER2- advanced or metastatic breast cancer
- HR+, HER2- node-positive early breast cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Abramson Cancer Center at Penn Medicine
Lead Sponsor
Abramson Cancer Center of the University of Pennsylvania
Lead Sponsor